[en] OBJECTIVES: We compare the symptomatic effects of 300 or 600mg daily of ASU in patients with knee osteoarthritis. METHODS: A multicenter, double blind, study comparing a daily intake of 300mg or 600mg of ASU and placebo. The study lasted 3 months and involved patients of both genders, aged 45 to 80 years and presenting with femoro-tibial knee osteoarthritis. The primary endpoint was NSAIDs and analgesics intake between D30 and D90. RESULTS: All efficacy parameters were significantly improved (p<0.01), in the two ASU groups compared to the placebo group. At D90, NSAIDs and analgesics intake decreased by more than 50% in 71% of the patients receiving ASU 300mg or 600mg, compared to 36% of the patients receiving placebo. From DO to D90 Lequesne's index dropped by 3.9 and 2.9 points in ASU 300mg and 600mg groups, respectively, against 1.6 in those receiving placebo. CONCLUSION: The efficacy of ASU at a dosage of 300mg/day and 600mg/day was consistently superior to that of placebo at all endpoints, with no differences observed between the two doses.
Disciplines :
General & internal medicine
Author, co-author :
Appelboom, T
Schuermans, J
Verbruggen, G
Henrotin, Yves ; Université de Liège - ULiège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartillage (U.R.O.C.)
REGINSTER, Jean-Yves ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Language :
English
Title :
Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study.
Altman R., Brandt K., Hochberg M., Moskowitz R., Bellamy N., Bloch D. (1996) Design and conduct of clinical trials in patients with osteoarthritis: Recommendations from task force of the Osteoarthritis Research Society. Results of a Workshop. Osteoarthritis Cartilage 4:217-243.
Lequesne M., Brandt K., Bellamy N., Moslowitz R., Menkes Pelletier J.P. (1994) Guidelines for testing slow acting drugs in osteoarthritis. J Rheumatol 21(SUPPL. 41):65-71.
Dougados M., Devogelaer J.P., Annefeld M., Avouac B., Bouvenot G., Cooper C. (1996) Recommendations for the registration of drugs used in the treatment of osteoarthristis. Ann Rheum Dis 55:552-557.
Bellamy N., Kirwan J., Airman R., Boers M., Brandt K., Brooks P. (1997) Recommendations for a score set of outcome measures for future phase III clinical trials in knee, hip and hand osteoarthritis. Results of consensus devlopment at OMERACT III. J Rheumatol 24:799-804.
Mauviel A., Daireaux M., Hartmann D., Galera P., Loyau G., Pujol J.P. (1989) Effets des insaponifiables d'avocat et de soja (IAS) sur la production de collagène par des cultures de synoviocytes, chondrocytes articulaires et fibroblastes dermiques. Rev Rhum Mal Ostéoartic 56:207-211.
Mauviel A., Loyau G., Pujol J.P. (1991) Effet des insaponifiables d'avocat/soja (PIASCLEDINE) sur l'activité collagénolytique de cultures de synoviocytes rhumatoïdes humains et de chondrocytes articulaires de lapin traités par l'interleukine 1. Rev Rhum Mal Ostéoartic 58:241-245.
Mazières B., Tempesta C., Tiechard M., Vaguier G. (1993) Pathologic and biochemical effects of a lipidic avocado and soya extract on an experimental post-contusive model of OA (résumé). Osteoarthritis Cartilage 1:46.
Boumédiene K., Felisaz N., Bogdanowicz P., Galera P., Guillou G., Pujol J.P. (1999) Avocado/soya unsaponifiables enhance the expression of transforming growth factor β1 and β2 in cultured articular chondrocytes. Arthritis Rheum 42:148-156.
Henrotin Y., Labasse A., Jaspar J., De Groote D., Zheng S., Guillou G. (1998) Effects of three avocado/soybean unsaponifiable mixtures on metalloproteinases, cytokines and progestaglandin E2 production by human articular chondrocytes. Clin Rheumatol 17:31-39.
Maheu E., Maziéres B., Valat J.P., Loyau G., Le Loët X., Bourgeois P. (1998) Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. A prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with six months treatment period and a two-month follow up demonstrating a persistent effect. Arthritis Rheum 41:81-91.
Blotman F., Maheu E., Wulwik A., Caspard H., Lopez A. (1997) Efficacite et tolérance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques. Essai prospectif, multicentrique, de trois mois, randomisé, en double insu, contrôlé versus placebo. Rev Rhum Mai Osteoartic 41:81-91.
Altman R., Asch E., Bloch D., Bole G., Borenstein D., Brandt K. (1986) Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the knee. Arthritis Rheum 29:1039-1049.
Dreiser R., Maheu E., Julien D. (1997) Proposition d'un score d'équivalence des anti inflammatoires non stéroïdiens (AINS) et des antalgiques dans l'arthrose. Rev Rhum 51:818.
Bakowsky V., Hanly J. (2000) Cox - 2 inhibition: Not too hot, not too cold - (Perhaps) just right?. J Rheumatol 27(SUPPL. 12):2734-2737.
